The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
Open accessAbstract
Aims/hypothesis We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein metabolism in patients with type 2 diabetes.Subjects, materials and methods This was a single-centre, randomised, double-blind study in drug-naive patients with type 2 diabetes. Patients received vildagliptin (50 mg twice daily, n=15) or placebo (n=16) for 4 weeks. Triglyceride, cholesterol, lipoprotein, glucose, insulin, glucagon and glucagon-like peptide-1 (GLP-1) responses to a fat-rich mixed meal were determined for 8 h postprandially before and after 4 weeks of treatment.Results Relative to placebo, 4 weeks of treatment with vildagliptin decreased the AUC(0-8h) for total trigyceride by 22+/-11% (p=0.037), the incremental AUC(0-8h) (IAUC(0-8h)) for total triglyceride by 85+/-47% (p=0.065), the AUC(0-8h) for chylomicron triglyceride by 65+/-19% (p=0.001) and the IAUC(0-8h) for chylomicron triglyceride by 91+/-28% (p=0.002). This was associated with a decrease in chylomicron apolipoprotein B-48 (AUC(0-8h), -1.0+/-0.5 mg l(-1) h, p=0.037) and chylomicron cholesterol (AUC(0-8h), -0.14+/-0.07 mmol l(-1) h, p=0.046). Consistent with previous studies, 4 weeks of treatment with vildagliptin also increased intact GLP-1, suppressed inappropriate glucagon secretion, decreased fasting and postprandial glucose, and decreased HbA(1c) from a baseline of 6.7% (change, -0.4+/-0.1%, p<0.001), all relative to placebo.Conclusions/interpretation Treatment with vildagliptin for 4 weeks improves postprandial plasma triglyceride and apolipoprotein B-48-containing triglyceride-rich lipoprotein particle metabolism after a fat-rich meal. The mechanisms underlying the effects of this dipeptidyl peptidase IV inhibitor on postprandial lipid metabolism remain to be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“Additionally, a four-week treatment with DPP-4 inhibitor vildagliptin was also found to induce reductions in the postprandial TG and apolipoprotein B-48 containing TG-rich lipoprotein particle metabolism after a fat meal [177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Self-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Self-citationAhrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Self-citationType 2 Diabetes as a “Coronary Heart Disease Equivalent”
Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2901 · Cited by 452
Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Self-citationMaggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · cited 3×
“This situation contrasts with the recent finding in healthy volunteers that exogenous GLP1 infusion (which increased plasma levels >10-fold) eliminated the postprandial increase in TGs [27].”
ResultInfluential
Cited by
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
O’Keefe, J. H., & Bell, D. S. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.107 · Cited by 538
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease
Han, T. S., & Lean, M. E. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016633371 · Cited by 500
Metadata
- Authors
- Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R.
- Affiliations
- Helsinki University Hospital (FI)
- Novartis (Switzerland) (CH)
- Corresponding author
- Taskinen, M.-R.
- Venue
- Diabetologia
- Published
- 2006-07-01
- Volume
- 49
- Issue
- 9
- Pages
- 2049-2057
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2152978153
- Cited by
- 336
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 2 · 2022: 8 · 2021: 5 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 15 · 2016: 24 · 2015: 23 · 2014: 34 · 2013: 38 · 2012: 29
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- DPP-4 inhibitors, type 2 diabetes, postprandial lipemia, triglyceride-rich lipoproteins, chylomicrons, apolipoprotein B-48, glucagon-like peptide-1, glucagon secretion, postprandial lipoprotein metabolism
- MeSH terms
- Vildagliptin, Adamantane, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Insulin, Intestinal Mucosa, Intestines, Lipids, Lipoproteins, Male, Middle Aged, Nitriles, Pyrrolidines, Time Factors, Triglycerides, Treatment Outcome, Postprandial Period, Glucagon-Like Peptide 1, Apolipoprotein B-48, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1007/s00125-006-0340-2
- The paper
- Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006). Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-006-0340-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.